Investor's Business Daily on MSN
IBD stock of the day Halozyme eyes two buy points; how it's layering up for future growth
Halozyme is Monday's IBD Stock Of The Day. Shares are flirting with a pair of entries after the drug delivery expert issued a ...
Skin and soft tissue infections are more common in children with Crohn’s disease, especially those receiving combination ...
Investor's Business Daily on MSN
IBD rating upgrades: Rogers Communications B shows improved price strength
A Relative Strength Rating upgrade for Rogers Communications B shows improving technical performance. Will it continue?
AstraZeneca made a big commitment to China as CEO Pascal Soriot joined British Prime Minister Keir Starmer on a trip to the ...
LGBTQ+ individuals with inflammatory bowel disease experience multiple gaps and inequities in care when managing their ...
Boehringer Ingelheim has penned a 1.05 billion euro ($1.26 billion) biobucks deal for Simcere’s preclinical inflammatory bowel disease (IBD) bispecific antibody. | Boehringer Ingelheim has penned a 1.
Among patients with IBD in self reported clinical remission, habitual meat intake may affect the risk for flares in those with ulcerative colitis, but not in those with Crohn's disease.
Appointments strengthen Palisade Bio's clinical strategy as PALI-2108 advances toward Phase 2 development in ulcerative colitis and fibrostenotic Crohn's disease, with a Phase 2 UC IND submission ...
For decades, patients with inflammatory bowel disease have reported a familiar and frustrating pattern: periods of intense ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results